NEMAURA MEDICAL INC (NMRD)

Company Profile

Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.

Company Info

NEMAURA MEDICAL INC

57 W 57th St

New York City NEW YORK 10019

CEO: Dewan Fazlul Hoque Chowdhury

Employees: 36

Website: https://nemauramedical.com/